https://www.wired.com/story/the-first-widespread-cure-for-hiv-could-be-in-children/ Skip to main content Wired SECURITY POLITICS THE BIG STORY BUSINESS SCIENCE CULTURE REVIEWS Wired Newsletters Security Politics The Big Story Business Science Culture Reviews More The Big InterviewMagazineThe New Era of Business TravelEventsWIRED InsiderWIRED Consulting Newsletters Podcasts Video Merch Search Sign In Sign In David Cox Science Aug 1, 2025 9:19 AM The First Widespread Cure for HIV Could Be in Children Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their viral loads to undetectable levels and then come off the medicine. KISUMU KENYA APRIL 24 HIVpositve Fiona Atieno Ochiri holds her ARV tablets a lifeline in her daily fight for control... An ARV tablet being held in Kisumu, Kenya, on April 24, 2025. Photograph: Michel Lunanga/Getty Images Save this story Save this story For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford pediatrician and immunologist began working with scientists in the South African province of KwaZulu-Natal, with the aim of tracking several hundred children who had acquired HIV from their mothers, either during pregnancy, childbirth, or breastfeeding. After putting the children on antiretroviral drugs early in their lives to control the virus, Goulder and his colleagues were keen to monitor their progress and adherence to standard antiretroviral treatment, which stops HIV from replicating. But over the following decade, something unusual happened. Five of the children stopped coming to the clinic to collect their drugs, and when the team eventually tracked them down many months later, they appeared to be in perfect health. "Instead of their viral loads being through the roof, they were undetectable," says Goulder. "And normally HIV rebounds within two or three weeks." In a study published last year, Goulder described how all five remained in remission, despite having not received regular antiretroviral medication for some time, and in one case, up to 17 months. In the decades-long search for an HIV cure, this offered a tantalizing insight: that the first widespread success in curing HIV might not come in adults, but in children. At the recent International AIDS Society conference held in Kigali, Rwanda, in mid-July, Alfredo Tagarro, a pediatrician at the Infanta Sofia University Hospital in Madrid, presented a new study showing that around 5 percent of HIV-infected children who receive antiretrovirals within the first six months of life ultimately suppress the HIV viral reservoir--the number of cells harboring the virus's genetic material--to negligible levels. "Children have special immunological features which makes it more likely that we will develop an HIV cure for them before other populations," says Tagarro. His thoughts were echoed by another doctor, Mark Cotton, who directs the children's infectious diseases clinical research unit at the University of Stellenbosch, Cape Town. "Kids have a much more dynamic immune system," says Cotton. "They also don't have any additional issues like high blood pressure or kidney problems. It makes them a better target, initially, for a cure." According to Tagarro, children with HIV have long been "left behind" in the race to find a treatment that can put HIV-positive individuals permanently into remission. Since 2007, 10 adults are thought to have been cured, having received stem cell transplants to treat life-threatening blood cancer, a procedure which ended up eliminating the virus. Yet with such procedures being both complex and highly risky--other patients have died in the aftermath of similar attempts--it is not considered a viable strategy for specifically targeting HIV. Instead, like Goulder, pediatricians have increasingly noticed that after starting antiretroviral treatment early in life, a small subpopulation of children then seem able to suppress HIV for months, years, and perhaps even permanently with their immune system alone. This realization initially began with certain isolated case studies: the "Mississippi baby" who controlled the virus for more than two years without medication, and a South African child who was considered potentially cured having kept the virus in remission for more than a decade. Cotton says he suspects that between 10 and 20 percent of all HIV-infected children would be capable of controlling the virus for a significant period of time, beyond the typical two to three weeks, after stopping antiretrovirals. Goulder is now launching a new study to try and examine this phenomenon in more detail, taking 19 children in South Africa who have suppressed HIV to negligible levels on antiretrovirals, stopping the drugs, and seeing how many can prevent the virus from rebounding, with the aim of understanding why. To date, he says that six of them have been able to control the virus without any drugs for more than 18 months. Based on what he's seen so far, he has a number of ideas about what could be happening. In particular, it appears that boys are more likely to better control the virus due to a quirk of gender biology to do with the innate immune system, the body's first-line defense against pathogens. "The female innate immune system both in utero and in childhood is much more aggressive than the male equivalent when it encounters and senses viruses like HIV," says Goulder. "Usually that's a good thing, but because HIV infects activated immune cells, it actually seems to make girls more vulnerable to being infected." In addition, Goulder notes that because female fetuses share the same innate immune system as their mothers, the virus transmitted to them is an HIV strain that has become resistant to the female innate immune response. There could also be other explanations for the long-lasting suppression seen in some children. In some cases, Goulder has observed that the transmitted strain of HIV has been weakened through needing to undergo changes to circumvent the mother's adaptive immune response, the part of the immune system which learns to target specific viruses and other pathogens. He has also noted that male infants experience particularly large surges of testosterone in the first six months of life--a period known as "mini-puberty"--which can enhance their immune system in various ways that help them fight the virus. Such revelations are particularly tantalizing as HIV researchers are starting to get access to a far more potent toolbox of therapeutics. Leading the way are so-called bNAbs, or broadly neutralizing antibodies, which have the ability to recognize and fight many different strains of HIV, as well as stimulating the immune system to destroy cells where HIV is hiding. There are also a growing number of therapeutic vaccines in development that can train the immune system's T cells to target and destroy HIV reservoirs. Children tend to respond to various vaccines better than adults, and Goulder says that if some children are already proving relatively adept at controlling the virus on the back of standard antiretrovirals, these additional therapeutics could give them the additional assistance they need to eradicate HIV altogether. In the coming years, this is set to be tested in several clinical trials. Cotton is leading the most ambitious attempt, which will see HIV-infected children receive a combination of antiretroviral therapy, three bNAbs, and a vaccine developed by the University of Oxford, while in a separate trial, Goulder is examining the potential of a different bNAb together with antiretrovirals to see whether it can help more children achieve long-term remission. "We think that adding the effects of these broadly neutralizing antibodies to antiretrovirals will help us chip away at what is needed to achieve a cure," says Goulder. "It's a little bit like with leukemia, where treatments have steadily improved, and now the outlook for most children affected is incredibly good. Realistically in most cases, curing HIV probably requires a few hits from different angles, impacting the way that the virus can grow, and tackling it with different immune responses at the same time to essentially force it into a cul-de-sac that it can't escape from." Children are also being viewed as the ideal target population for an even more ambitious experimental treatment, a one-time gene therapy that delivers instructions directing the body's own muscle cells to produce a continuous stream of bNAbs, without the need for repeated infusions. Maurico Martins, an associate professor at the University of Florida, who is pioneering this new approach, feels that it could represent a particularly practical strategy for low-income countries where HIV transmission to children is particularly rife, and mothers often struggle to keep their children on repeated medication. "In regions like Uganda or parts of South Africa where this is very prevalent, you could also give this therapy to a baby right after birth as a preventative measure, protecting the newborn child against acquisition of HIV through breastfeeding and maybe even through sexual intercourse later in life," says Martins. While Martins also hopes that gene therapy could benefit HIV-infected adults in future, he feels it has more of a chance of initially succeeding in children because their nascent immune systems are less likely to launch what he calls an anti-drug response that can destroy the therapeutic bNAbs. "It's very difficult for most antibodies to recognize the HIV envelope protein because it's buried deep within a sugar coat," says Martins. "To overcome that, these bNAbs carry a lot of mutations and extensions to their arms which allow them to penetrate that sugar coat. But the problem then is that they're often viewed by your own immune system as foreign, and it starts making these anti-bNAb antibodies." But when Martins tested the therapy in newborn rhesus macaques, it was far more effective. "We found that the first few days or two weeks after birth comprised a sort of sweet spot for this gene therapy," he says. "And that's why this could really work very well in treating and preventing pediatric HIV infections." Like many HIV scientists, Martins has run into recent funding challenges, with a previous commitment from the National Institutes of Health to support a clinical trial of the novel therapy in HIV-infected children being withdrawn. However, he is hoping that the trial will still go ahead. "We're now talking with the Gates Foundation to see whether they can sponsor it," he says. While children still comprise the minority of overall HIV infections, being able to cure them may yield further insights that help with the wider goal of an overall curative therapy. "We can learn a lot from them because they are different," says Goulder. "I think we can learn how to achieve a cure in kids if we continue along this pathway, and from there, that will have applications in adults as well." You Might Also Like ... * In your inbox: Five new newsletters by deeply sourced experts * Interview: Bryan Johnson is going to die * Big Story: The enshittification of American power * This is DOGE 2.0 * Special Edition: Are we healthy yet? TopicssciencehealthHIVinfectious diseasechildren Read More The Grave Long-Term Effects of the Gaza Malnutrition Crisis The Grave Long-Term Effects of the Gaza Malnutrition Crisis The WHO believes one in five children in Gaza are acutely malnourished, with the health effects potentially lasting for generations. David Cox The Hyperflexible People Who May Help Unlock Better Sleep Apnea Treatments The Hyperflexible People Who May Help Unlock Better Sleep Apnea Treatments Patients with Ehlers-Danlos Syndrome are six times more at risk for the sleeping disorder. Now scientists are studying them in hopes of finding remedies beyond the CPAP machine. David Cox What Your Nighttime Breathing Says About Your Health What Your Nighttime Breathing Says About Your Health Once dismissed as just snoring, sleep apnea is now emerging as an early warning sign for serious conditions like Alzheimer's, heart disease, and depression. Anna McKie An Inventor Is Injecting Bleach Into Cancerous Tumors&-and Wants to Bring the Treatment to the US An Inventor Is Injecting Bleach Into Cancerous Tumors--and Wants to Bring the Treatment to the US A Chinese man with no medical training is injecting cancer patients with a toxic bleach solution; a full course of treatment runs $20,000. He's now working to bring the unproven treatment to the US. David Gilbert Florida Is Now a Haven for Unproven Stem-Cell Treatments Florida Is Now a Haven for Unproven Stem-Cell Treatments In a measure that flouts the FDA, Florida says doctors can give unapproved stem-cell therapies for wound care, pain management, or orthopedic purposes. Emily Mullin Scientists Succeed in Reversing Parkinson's Symptoms in Mice Scientists Succeed in Reversing Parkinson's Symptoms in Mice The findings of two recent studies give hope that the disease could one day be reversed in humans--but experts warn that this complex disease will likely need multiple complementary treatments. Fernanda Gonzalez Animals Are the Original Wellness Influencers Animals Are the Original Wellness Influencers Long before TikTok and probiotics, animals were teaching each other tips on feeling better, from swallowing leaves to get rid of parasites to using icebergs for exfoliation. Cara Giaimo States Are Moving to Protect Access to Vaccines States Are Moving to Protect Access to Vaccines As federal vaccine policy shifts under US health secretary Robert F. Kennedy Jr., lawmakers are looking to give state-level public health officials authority to ignore federal recommendations. Emily Mullin Can US Measles Outbreaks Be Stopped? Can US Measles Outbreaks Be Stopped? The US almost lost its measles elimination status once. Lessons from that episode suggest it will be more difficult to avoid doing so now. Emily Mullin Why Jolly Ranchers Are Banned in the UK but Not the US Why Jolly Ranchers Are Banned in the UK but Not the US Crude-oil-derived substances in the candy have been linked to health problems--and the regulations that have allowed their use in the US are now in Robert F. Kennedy Jr.'s crosshairs. Alex Christian Newly Discovered 'Infinity Galaxy' Could Prove How Ancient Supermassive Black Holes Formed Newly Discovered 'Infinity Galaxy' Could Prove How Ancient Supermassive Black Holes Formed This collision of two galaxies could demonstrate that theorized "direct collapse black holes" exist. Jorge Garay Measles Cases Are Soaring in Mexico Measles Cases Are Soaring in Mexico The disease has claimed the lives of 12 people in the country this year, with the virus continuing to spread rapidly. Fernanda Gonzalez WIRED WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is changing every aspect of our lives--from culture to business, science to design. The breakthroughs and innovations that we uncover lead to new ways of thinking, new connections, and new industries. More From WIRED * Subscribe * Newsletters * Travel * FAQ * WIRED Staff * WIRED Education * Editorial Standards * Archive * RSS * Accessibility Help Reviews and Guides * Reviews * Buying Guides * Mattresses * Electric Bikes * Soundbars * Streaming Guides * Wearables * TVs * Coupons * Gift Guides * Advertise * Contact Us * Manage Account * Jobs * Press Center * Conde Nast Store * User Agreement * Privacy Policy * Your California Privacy Rights (c) 2025 Conde Nast. All rights reserved. WIRED may earn a portion of sales from products that are purchased through our site as part of our Affiliate Partnerships with retailers. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Conde Nast. Ad Choices Select international site United States * Italia * Japon * Czech Republic & Slovakia * * * * * *